...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Economic evaluation of tandem mass spectrometry newborn screening in australia.
【24h】

Economic evaluation of tandem mass spectrometry newborn screening in australia.

机译：澳大利亚串联质谱新生儿筛查的经济评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: The goal was to investigate the cost-effectiveness of tandem mass spectrometry screening for the detection of inborn metabolic errors in an Australian setting. METHODS: Cost-effectiveness analysis from the health service perspective was undertaken on the basis of registry data for affected individuals. The intervention group was contrasted with both a contemporaneous group in nonscreening states and a historical cohort. The registry covers all individuals identified in Australia between 1994 and 2002. Main outcome measures were the total net cost of screening, the cost of treatment, life-years saved, and deaths averted. RESULTS: The total net cost of testing was estimated to be ADollars 218 000 per 100 000 infants. Medical costs incurred by the intervention group exceeded those for the control group by ADollars 131 000 per 100 000 infants. The number of life-years saved per 100 000 infants screened was 32.378 life-years per 100 000 infants through an expected mortality rate reduction of 0.738 deaths per 100 000 infants. The cost per death averted was estimated to be ADollars 472 913 and the cost per life-year saved was estimated to be ADollars 10 779, which compare favorably with existing cost-effectiveness standards. This conclusion is particularly robust because conservative assumptions were made throughout, because of data limitations. Sensitivity analyses suggested that this result was relatively robust to adjustment of model parameters. CONCLUSIONS: Tandem mass spectrometry screening for conditions caused by rare errors of metabolism is likely to be a cost-effective intervention in Australia.
机译：目的：目的是研究串联质谱筛查在澳大利亚环境中检测先天性代谢错误的成本效益。方法：从卫生服务的角度进行了成本效益分析，是基于针对受影响个人的注册表数据。干预组与非筛查州同期组和历史队列进行了对比。该登记册覆盖了1994年至2002年在澳大利亚确定的所有个人。主要结果指标是筛查的总净费用，治疗费用，挽救的生命年数和避免的死亡人数。结果：测试的总净成本估计为每10万婴儿21.8万阿杜拉尔。干预组的医疗费用比对照组高出每十万名婴儿131 000 ADollars。通过将每10万婴儿的预期死亡率降低0.738例死亡，每筛选10万婴儿所挽救的生命年数量为每10万婴儿32.378个生命年。避免的每人死亡成本估计为ADollars 472913，而每生命年节省的成本估计为ADollars 10779，这与现有成本效益标准相比是有利的。该结论特别可靠，因为由于数据限制，始终进行了保守的假设。敏感性分析表明，该结果对于模型参数的调整相对可靠。结论：串联质谱筛查由罕见的新陈代谢错误引起的疾病在澳大利亚可能是一种具有成本效益的干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号